Literature DB >> 2242564

Study of lipoprotein particles LpAI and LpAI:AII in patients before coronary bypass surgery.

M Coste-Burel1, F Mainard, L Chivot, J L Auget, Y Madec.   

Abstract

Lipids, apolipoproteins, and LpAI and LpAI:AII particles were studied in 43 men (mean age 51, SD 7, years) 24 h before their coronary bypass surgery and in 54 control men (mean age 46 SD 9, years). LpAI and LpAI:AII were analyzed by electroimmunodiffusion and by a noncompetitive enzyme-linked immunoassay, respectively. Concentrations of LpAI and LpAI:AII in the bypass patients were significantly lower (P less than 0.001) than those in the controls. Apolipoprotein AI was significantly correlated with LpAI (P less than 0.001) and LpAI:AII (P less than 0.01) in controls, but only with LpAI:AII (P less than 0.001) in bypass patients. Discriminant analysis between controls and patients showed apolipoprotein AI to be the most powerful discriminant factor; the addition of LpAI and LpAI:AII did not improve discriminant power. We conclude that the determination of LpAI and LpAI:AII particles reflects metabolic disorders in patients but does not significantly influence the discrimination of such patients into risk groups.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2242564

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  6 in total

Review 1.  Speciated High-Density Lipoprotein Biogenesis and Functionality.

Authors:  C Rosales; W S Davidson; B K Gillard; A M Gotto; H J Pownall
Journal:  Curr Atheroscler Rep       Date:  2016-05       Impact factor: 5.113

2.  Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene.

Authors:  J P Bossu; F L Chartier; J C Fruchart; J Auwerx; B Staels; B Laine
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

3.  Limited discriminant value of lipoprotein AI, lipoprotein Lp(a) and other lipoprotein particles in patients with and without early onset ischaemic heart disease.

Authors:  D T Vallance; H A Staunton; A F Winder
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

Review 4.  The concept of apolipoprotein-defined lipoprotein families and its clinical significance.

Authors:  Petar Alaupovic
Journal:  Curr Atheroscler Rep       Date:  2003-11       Impact factor: 5.113

5.  ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator.

Authors:  Toshimi Kido; Kazuo Kondo; Hideaki Kurata; Yoko Fujiwara; Takeyoshi Urata; Hiroshige Itakura; Shinji Yokoyama
Journal:  Lipids Health Dis       Date:  2017-11-29       Impact factor: 3.876

6.  Bioinformatic Analysis of Plasma Apolipoproteins A-I and A-II Revealed Unique Features of A-I/A-II HDL Particles in Human Plasma.

Authors:  Toshimi Kido; Hideaki Kurata; Kazuo Kondo; Hiroshige Itakura; Mitsuyo Okazaki; Takeyoshi Urata; Shinji Yokoyama
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.